Bank of America
CLDI icon

Bank of America’s Calidi Biotherapeutics CLDI Stock Holding History

Bank of America’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46
Closed -$53 – 5934
2025
Q4 		$53 Buy
46
+16
+53% +$24 ﹤0.01% 6945
2025
Q3 		$46 Buy
30
+3
+11% +$13 ﹤0.01% 8026
2025
Q2 		$75 Buy
27
+8
+42% +$39 ﹤0.01% 8024
2025
Q1 		$126 Sell
19
-69
-78% -$787 ﹤0.01% 7785
2024
Q4 		$1.22K Buy
88
+84
+2,100% +$1.57K ﹤0.01% 7258
2024
Q3 		$55 Buy
4
+2
+100% +$35 ﹤0.01% 7821
2024
Q2 		$55 Buy
+2
New +$64 ﹤0.01% 7819
2023
Q4 		– Sell
-1
Closed -$332 – 8025
2023
Q3 		$332 Buy
+1
New +$1.01K ﹤0.01% 7360

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America's CLDI Position: Q1 2026 in Review

Bank of America sold out of Calidi Biotherapeutics (CLDI) in Q1 2026, closing a stake of 46 shares — an estimated $53 sold.

Bank of America first reported a position in CLDI in Q3 2023 and held it in 8 quarters. The position peaked at $1.22K in Q4 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Bank of America reported no remaining Calidi Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 46 Calidi Biotherapeutics shares in Q1 2026, an estimated $53.
  • Bank of America first reported a position in Calidi Biotherapeutics in Q3 2023 and held it in 8 quarters.
  • Bank of America's Calidi Biotherapeutics position peaked at $1.22K in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.